Future prospects for pharmacogenetics in the quest for personalized medicine

Journal of Psychosocial Nursing and Mental Health Services

Volumn 50, Issue 12, 2012, Pages 13-16

  Howland, Robert H ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870898815     PISSN: 02793695     EISSN: None     Source Type: Journal    
DOI: 10.3928/02793695-20121114-01     Document Type: Article

References (15)

1. Boks, M.P., de Jong, N.M., Kas, M.J., Vink-ers, C.H., Fernandes, C., Kahn, R.S.,. Ophoff, RA. (2012). Current status and future prospects for epigenetic psychopharmacology. Epigenetics, 7, 20-28.doi:10.4161/epi.7.1.18688
2. Court, M.H. (2007). A pharmacogenomics primer. Journal of Clinical Pharmacology, 47, 1087-1103. doi:10.1177/0091270007303768
3. Csoka, A.B., & Szyf, M. (2009). Epigenetic side-effects of common pharmaceuticals: A potential new field in medicine and pharmacology. Medical Hypotheses, 73, 770-780. doi:10.1016/j.mehy.2008.10.039
4. Ecker, J.R., Bickmore, W.A., Barroso, I., Pritchard, J.K., Gilad, Y., & Segal, E. (2012). Genomics: ENCODE explained. Nature, 489(7414), 52-55. doi:10.1038/489052a
5. Grayson, D.R., Kundakovic, M., & Sharma, R.P. (2010). Is there a future for histone deacety-lase inhibitors in the pharmacotherapy of psy-chiatric disorders? Molecular Pharmacology, 77, 126-135. doi:10.1124/mol.109.061333
6. Helsby, N.A., & Burns, K.E. (2012). Molecular mechanisms of genetic variation and tran-scriptional regulation of CYP2C19 (Article 206). Frontiers in Genetics, 3. doi:10.3389/fgene.2012.00206
7. Joober, R., & Boksa, P. (2009). A new wave in the genetics of psychiatric disorders: The copy number variant tsunami. Journal of Psychiatry & Neurosciences, 34, 55-59.
8. Keers, R., & Uher, R. (2012). Gene-environment interaction in major depression and antidepressant treatment response. Current Psychiatry Reports, 14, 129-137. doi:10.1007/s11920-011-0251-x
9. Kurita, M., Holloway, T., García-Bea, A., Kozlenkov, A., Friedman, A.K., Moreno, J.L.,. González-Maseo, J. (2012). HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activity. Nature Neuroscience, 15, 1245-1254. doi:10.1038/nn.3181
10. Lane, H.Y., Tsai, G.E., & Lin, E. (2012). Assessing gene-gene interactions in pharmacoge-nomics. Molecular Diagnosis and Therapy, 16, 15-27.
11. McGowan, P.O., & Szyf, M. (2010). The epigenetics of social adversity in early life: Impli-cations for mental health outcomes. Neurobiology of Disease, 39, 66-72.
12. Motsinger, A.A., Ritchie, M.D., & Reif, D.M. (2007). Novel methods for detecting epistasis in pharmacogenomics studies. Pharmacoge-nomics, 8, 1229-1241.
13. Narayan, P., & Dragunow, M. (2010). Pharma-cology of epigenetics in brain disorders. British Journal of Pharmacology, 159, 285-303.
14. Ouahchi, K., Lindeman, N., & Lee, C. (2006). Copy number variants and pharma-cogenomics. Future Medicine, 7, 25-29. doi:10.2217/14622416.7.1.25
15. Tang, W., Hu, Z., Muallem, H., & Gulley, M.L. (2011). Clinical implementation of RNA signatures for pharmacogenomics decision-making. Pharmacogenomics and Personalized Medicine, 4, 95-107. doi:10.2147/PGPM.S14888